Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 53Neoplasms 23Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Lung Neoplasms 12Head and Neck Neoplasms 11Neoplasm Metastasis 8Carcinoma, Squamous Cell 7Pancreatic Neoplasms 6Colorectal Neoplasms 6Stomach Neoplasms 5Esophageal Squamous Cell Carcinoma 5Prostatic Neoplasms 4Multiple Myeloma 4Esophageal Neoplasms 4Lymphoma 3Hematologic Neoplasms 3Glioblastoma 3Brain Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Melanoma 2Glioma 2Colonic Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × PFS × Afatinib × Clear all
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡